82294-70-0Relevant articles and documents
Synthesis method of 4-methylthiazole-5-formaldehyde
-
Paragraph 0028; 0031; 0034-0036; 0039-0041; 0044-0045, (2021/05/01)
The invention provides a synthesis method of 4-methylthiazole-5-formaldehyde. The method comprises the following steps: 1) dissolving 4-methylthiazole-5-ethanol in a solvent, and carrying out oxidation reaction in the presence of a catalyst to obtain 4-methylthiazole-5-acetic acid; and 2) carrying out heating reaction on the 4-methylthiazole-5-acetic acid obtained in the step 1) in the presence of oxygen and a metal salt catalyst to obtain the 4-methylthiazole-5-formaldehyde. According to the method, 4-methylthiazole-5-ethanol is used as a raw material, the raw material is green, cheap and easy to obtain, the reaction process is mild in condition and environmentally friendly, the result selectivity is good, the yield is high, good economic benefits are achieved, and the method is suitable for industrial production.
Novel preparation method for 4-methylthiazole-5-carboxaldehyde
-
Paragraph 0040; 0045; 0046; 0047; 0048; 0049; 0050, (2019/01/14)
The invention discloses a novel preparation method of 4-methylthiazole-5-carboxaldehyde. The novel preparation method includes the steps of subjecting 2-amino-4-methylthiazole to amino methylation toobtain 2-methylamino-4-methylthiazole, subjecting the 2-methylamino-4-methylthiazole to Vilsmeier reaction to obtain 2-methylamino-4-methyl-5-thiazolecarboxaldehyde, and hydrogenating the 2-methylamino-4-methyl-5-thiazolecarboxaldehyde to remove methylamino to obtain the 4-methylthiazole-5-carboxaldehyde. The preparation method has the advantages of moderate reaction condition, high yield, less generated waste and suitability for mass industrial production.
HETEROARYL COMPOUNDS AS PDE10A INHIBITORS
-
Page/Page column 39, (2011/11/06)
The present invention provides heteroaryl compounds as Phosphodiesterase 10A (PDE I OA) inhibitors. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders by inhibiting Phosphodiesterase 10A enzyme. Also provided herein are processes for preparing compounds described herein, Formula (I), intermediates used in their synthesis, pharmaceutical compositions thereof.